Merus
Founded Year
2003Stage
Corporate Minority - P2P | IPOTotal Raised
$145.5MAbout Merus
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional IgG-based antibodies, such as long half-life and low immunogenicity. Merus's lead Biclonics product candidate, MCLA-128 is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus's second Biclonics product candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia, and Merus expects to initiate clinical trials of this candidate in the first quarter of 2016. The company also has a robust pipeline of proprietary product candidates in pre-clinical development, including Biclonics designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Merus Patents
Merus has filed 82 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immunology
- Monoclonal antibodies
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/6/2018 | 9/12/2023 | Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Oncology, Infectious causes of cancer | Grant |
Application Date | 7/6/2018 |
|---|---|
Grant Date | 9/12/2023 |
Title | |
Related Topics | Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Oncology, Infectious causes of cancer |
Status | Grant |
Latest Merus News
Aug 31, 2023
Merus to Participate in Upcoming Investor Conferences 5-day change Today at 08:01 am Share UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ET Morgan Stanley 21st Annual Global Healthcare Conference: Wednesday, September 13 12:55-1:25 p.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event. About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter. Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V. Share
Merus Frequently Asked Questions (FAQ)
When was Merus founded?
Merus was founded in 2003.
Where is Merus's headquarters?
Merus's headquarters is located at Padualaan 8, Utrecht.
What is Merus's latest funding round?
Merus's latest funding round is Corporate Minority - P2P.
How much did Merus raise?
Merus raised a total of $145.5M.
Who are the investors of Merus?
Investors of Merus include Eli Lilly and Company, Aglaia Oncology Funds, Bay City Capital, Pfizer Venture Investments, Novartis Venture Funds and 10 more.
Who are Merus's competitors?
Competitors of Merus include Invistics, Cevec Pharmaceuticals, Ambrx, OcuNexus Therapeutics, ImmunoReagents, Symphogen, Adello Biologics, Affimed Therapeutics, Xencor, Fate Therapeutics and 19 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Merus to Competitors
ImmunoReagents is a cGMP manufacturing facility for antibodies used in the In Vitro Diagnostic Industry, which specializes in polyclonal antibodies to human proteins and secondary antibodies.
Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.
Oxford BioTherapeutics is an international, clinical-stage biotechnology company focused on developing antibody-based therapies to treat cancer. Combining immuno-oncology, antibody-drug conjugates, and fully human monoclonal antibody approaches against novel human tumor cell membrane-derived checkpoint targets identified using its unique target selection and validation platform, the Company has gathered compelling in vivo evidence of the potency of its broad pipeline.
Neuronyx is focused on developing biomedicines by harnessing the therapeutic potential of the human cell.
Oxyrane is a biopharmaceutical company dedicated to the development of biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases.
Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
